一分钟看懂
这是一项关于宫颈癌的III 期研究，登记的药物或干预包括GLS-010；Placebo；paclitaxel；cisplatin；carboplatin；bevacizumab，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
GLS-010；Placebo；paclitaxel；cisplatin；carboplatin；bevacizumab · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Hospital · 上海
公开的入选条件
- 1. Signed the informed consent form.
- 2. Women aged ≥ 18 and ≤ 75 years.
- 3. ECOG of 0 or 1.
- 4. Life expectancy ≥ 12 weeks.
- 5. Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1),.The histological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma.
- 6. No prior systemic therapy for persistent, recurrent or metastatic (\[FIGO\] Stage IVB) disease,not amenable to curative surgery or concurrent chemoradiotherapy.
- 7. At least one measurable tumor lesion per RECIST v1.1; lesions previously treated with radiotherapy or other loco-regional therapy are not considered as target lesions unless the lesion has unequivocal progression or the biopsy is obtained to confirm maligan
- 8. Subjects must have adequate organ function.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05798819；登记信息更新于 2026-09-16。